Related Experiment Video
Updated: Jun 16, 2026
07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
Gastric bypass and glucose metabolism
R Caiazzo1, C Zerrweck, R Verhaeghe
1Univ Lille Nord, Lille, France.
Diabetes & Metabolism
|February 16, 2010
Summary
Gastric bypass surgery effectively treats severe obesity and remarkably improves glucose metabolism in type 2 diabetes patients, often leading to diabetes remission. This report details the procedure and explores its metabolic mechanisms.
Area of Science:
- Metabolic surgery
- Bariatric procedures
- Endocrinology
Background:
- Gastric bypass (GBP) surgery is primarily a weight-loss intervention for severe obesity.
- A significant secondary effect of GBP is its impact on glucose metabolism.
- Many patients with type 2 diabetes experience diabetes remission after GBP.
Purpose of the Study:
- To outline the fundamental surgical principles of gastric bypass.
- To summarize the proposed mechanisms behind GBP's effect on glucose metabolism.
- To highlight GBP as a treatment for type 2 diabetes.
Main Methods:
- Review of surgical techniques for gastric bypass.
- Analysis of physiological and hormonal changes post-GBP.
- Literature synthesis on diabetes remission following bariatric surgery.
Main Results:
- Gastric bypass involves altering the digestive tract to reduce stomach size and bypass part of the small intestine.
- Post-GBP, significant improvements in insulin sensitivity and glucose regulation are observed.
- High rates of type 2 diabetes remission are documented in patients undergoing GBP.
Conclusions:
- Gastric bypass surgery offers substantial benefits for type 2 diabetes management beyond weight loss.
- The mechanisms involve complex changes in gut hormones, nutrient absorption, and metabolic signaling.
- GBP represents a powerful therapeutic option for select patients with obesity and type 2 diabetes.
Related Concept Videos
01:02Glucose Homeostasis: Regulation of Blood Glucose
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Glucose Absorption Into the Small Intestine
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and 'exit' via the...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:19Overview of Carbohydrate Metabolism
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...